Safety and efficacy of different albendazole-based treatment regimens to reduce microfilaraemia in subjects infected by Loa loa in an Gabo

Phase 2

Completed

• Conditions: Eye infection; LoaLoa

• Registration Number: PACTR201807197019027
• Lead Sponsor: Ayola Akim Adegnika

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-06-07
• Last Update Posted: 2023-05-29

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 42

Inclusion Criteria

Adult, male participants in the BuDiLoLo study
-L. loa microfilaria < 50,000 mf/mL
-Intention to remain residing in study area and comply with study procedures throughout 6 month follow-up period
-Signed written informed consent

Exclusion Criteria

-Patients treated with albendazole during the 4 previous weeks
-Known intolerance or allergy to any study drug
-Viral hepatitis (HBV, HCV) or other known active liver disease
-HIV or other known immunosuppressive condition
-History of epilepsy, encephalitis, meningitis or encephalopathy
-Any other acute or chronic medical condition, medication or psychosocial factor(s) deemed by the Investigator to put the potential participant at greater than acceptable risk or to significantly affect study outcomes

Study & Design

• Study Type: Interventional
• Study Design: Not specified